ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31

ANGIODYNAMICS INC

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026

$11.39+0.15 (+1.33%)

Close on Oct 19, 2026

Market cap: $478.63M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Aug 31, 2026

Angiodynamics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Angiodynamics's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Angiodynamics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ANGO.

Revenue growth8.2% · median 13.9%

Gross margin55.7% · median 72.9%

Operating margin-11.2% · median 2.3%

Net margin-10.1% · median 0.6%

Company	Revenue	Growth
ATRC	$569.62M	+13.9%
AORT	$471.47M	+16.4%
ARAY	$401.95M	-12.3%
ANGO	$325.38M	+8.2%
LMAT	$262.43M	+11.8%
DCTH	$95.42M	+35.8%

Company

Next earnings (est.): Jan 5, 2027, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: May 31
Employees: 632
Held by institutions: 91.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1275187

Advertisement
300 × 250